# **Special Issue**

## Recent Advances in Cancer Metastasis Models

## Message from the Guest Editor

Cancer metastasis remains the leading cause of cancer-related mortality worldwide. Despite extensive research efforts, our understanding of the mechanisms that drive metastatic dissemination, colonization, and resistance to therapy is still evolving. Traditional experimental models have provided critical insights but often fall short in recapitulating the complexity of human metastatic disease.

This Special Issue aims to highlight recent innovations in cancer metastasis modeling, ranging from advanced in vitro platforms such as 3D culture systems and organoids to in vivo animal models and integrative computational approaches. In particular, the incorporation of artificial intelligence, machine learning, and multi-omics data has opened new avenues to improving the predictive power and translational relevance of metastasis research.

We invite contributions that explore the biological, molecular, and technological foundations of metastasis modeling, with the goal of enhancing our ability to study, predict, and ultimately intervene in metastatic progression.

#### **Guest Editor**

Dr. Lin Zhang

The School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia

## Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/254723

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





## **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).